The purpose is to find out whether the drug can improve liver health and reduce scarring after about one year of treatment. People in the trial are randomly placed into one of three groups and receive either the active drug, the dummy injection, or another dose level, without knowing which they get. Over the study period, they have regular visits for blood tests, imaging scans such as MRI, and occasional liver biopsies to check for changes in inflammation and scarring, while safety is closely monitored.

The purpose of the study is to find out whether the new medicine can improve lung function and reduce the number of worsening episodes compared with the placebo. Participants will be randomly assigned to receive either the study drug or the placebo, and neither the participants nor the study staff will know which one is given. The treatment period lasts several months, during which participants will attend regular visits for breathing tests, answer health questionnaires, and have safety checks for any side effects.

Key measurements include the forced expiratory volume in one second (FEV1), a test that measures how much air can be forcefully exhaled in one second and indicates how well the lungs are working. The study also tracks the rate of ECOPD, which are episodes when symptoms get much worse and may require extra medical care. Participants will complete questionnaires such as the Saint Georges Respiratory Questionnaire (SGRQ) and the COPD assessment test (CAT) to assess how the disease affects daily life. All safety information, including any side effects, will be closely monitored throughout the study.

During the study, participants will be assigned to receive either depemokimab or a placebo through a subcutaneous injection, which is a shot given just under the skin. The study is designed so that neither the participants nor the researchers know which treatment is being administered. This approach helps ensure that the results are as accurate as possible.

The purpose of the study is to see if the new combination can keep the cancer from getting worse for a longer time than the standard treatments. Participants are randomly assigned to receive either the new three‑drug regimen or the standard therapy, and they take the medicines in repeated cycles while visiting the clinic for regular check‑ups and imaging scans. The main result being measured is progression‑free survival (PFS), which means the time until the cancer grows or the patient dies, and it is evaluated using standard imaging rules called RECIST and analyzed with the Kaplan‑Meier statistical method. Safety and side‑effects are recorded and graded according to the CTCAE system.

The purpose of the study is to assess how effective and safe sonelokimab is for adults with moderate to severe hidradenitis suppurativa. Participants in the study will receive either sonelokimab or a placebo over a period of 16 weeks. During this time, researchers will monitor the participants to see if there is a 75% improvement in their condition, which is measured by a specific score called the Hidradenitis Suppurativa Clinical Response (HiSCR) score. The study will also track any side effects or adverse events that occur during the treatment period.

Throughout the study, participants will undergo regular check-ups, including physical examinations and laboratory tests, to ensure their safety and to gather data on the treatment’s effects. The trial aims to provide valuable information on whether sonelokimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa, potentially improving their quality of life by reducing the severity of their symptoms.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 capsules or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a double-blind study. The study will take place over a period of time, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

Throughout the study, participants will be asked to take the medication orally, in capsule form, and will be regularly assessed by healthcare professionals. The study aims to provide valuable information on whether AVP-786 can be a beneficial treatment option for managing agitation in patients with Alzheimer’s disease. The results will help determine if this medication can improve the quality of life for those affected by this condition.

The study is divided into two phases. In the first phase, participants will receive either PLS240 or a placebo to compare the effects. This phase is designed to see if PLS240 can effectively lower PTH levels by at least 30%. In the second phase, which is open-label, all participants will receive PLS240 to further assess its long-term safety. Participants will receive the medication through an intravenous injection, which means it will be administered directly into a vein using a pre-filled syringe.

The trial will last for a maximum of 53 weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment. These check-ups will include laboratory tests, physical exams, and monitoring of vital signs. The goal is to ensure the treatment is both effective and safe for individuals with secondary hyperparathyroidism undergoing hemodialysis.

Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of time, during which participants will take the medication orally in the form of a modified-release tablet. The goal is to observe any changes in the severity of eczema symptoms and overall skin condition over the course of the study.

Throughout the study, participants will be monitored for any improvements in their eczema symptoms, such as reduced itching and inflammation, as well as any potential side effects. The study aims to provide valuable information on whether Upadacitinib can be an effective treatment option for those suffering from moderate to severe eczema. By participating in this study, researchers hope to gain insights that could lead to better management and treatment options for individuals with this challenging skin condition.

Participants in the study will receive either secukinumab or a placebo. The study will last for 24 weeks, during which the effects of the treatment on shoulder symptoms will be monitored. The main focus will be on changes in physical symptoms related to the shoulder, assessed at different points throughout the study. Participants will be asked to continue any existing treatments, such as non-steroidal anti-inflammatory drugs (NSAIDs) and physiotherapy, at a stable dosage and regimen.

The study will also involve monitoring the safety and tolerability of secukinumab, including any side effects or changes in laboratory results. Participants will have their progress evaluated through various assessments, including the Western Ontario Rotator Cuff Index (WORC) and the Patient-Reported Outcomes Measurement Information System (PROMIS). The study aims to provide valuable insights into the potential benefits of secukinumab for individuals with rotator cuff tendinopathy.

Participants in the study will be randomly assigned to receive either IMU-838 or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will monitor the time it takes for participants to experience their first relapse, which is a return of symptoms after a period of improvement. This will help determine if IMU-838 can delay these relapses.

Throughout the study, participants will undergo various assessments, including MRI scans, to track changes in the brain and measure the effectiveness of the treatment. The study will also look at other factors, such as changes in disability levels and brain volume, to gather comprehensive data on the impact of IMU-838 on Relapsing Multiple Sclerosis. The study is expected to continue for several years to gather sufficient data on the long-term effects of the treatment.

The purpose of the study is to determine the dose at which the two inhaled forms provide a similar amount of levodopa in the body. Healthy adult volunteers will receive a single dose of each product on separate occasions, with a short break between each period. Before each inhaled dose, participants will take carbidopa by mouth about one hour earlier while fasting (no food). The study will record how quickly the medicine appears in the blood and will monitor safety through basic medical checks.